Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.31 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.30 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401808 | 0.84 | LMNA (0.33) | SLC29A1 | |
| SCHEMBL6403256 | 0.82 | DUT (0.40) | DUTTDP1P2RY14SLC28A1SLC28A2 | |
| SCHEMBL6401482 | 0.70 | SLC28A1 (0.59) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6401489 | 0.70 | SLC28A1 (0.59) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23243924 | 0.64 | SLC28A1 (0.45) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23069347 | 0.62 | SLC28A1 (0.43) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18057138 | 0.62 | P2RY6 (0.38) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23710619 | 0.61 | DUT (0.45) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21418938 | 0.61 | DUT (0.48) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL20503160 | 0.61 | DUT (0.52) | DUTP2RY14SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | DUT 5/4885TDP1 1161/4885P2RY14 694/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | DUT 6/4885TDP1 1182/4885P2RY14 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.